Memory Enhancement Using Transcranial Alternating Current Stimulation (Memento)

A

Amsterdam UMC, location VUmc

Status

Not yet enrolling

Conditions

Alzheimer Disease
Mild Cognitive Impairment

Treatments

Device: Gamma (40 Hz) tACS at the precuneus region
Device: Sham tACS at the precuneus region

Study type

Interventional

Funder types

Other

Identifiers

NCT06202872
20212222

Details and patient eligibility

About

The 32 million Alzheimer's disease (AD) and 69 million prodromal AD patients worldwide contribute to a large economic burden. Effective and safe therapies that slow or prevent the progression from mild cognitive impairment (MCI) to AD are therefore of high priority. Transcranial alternating current stimulation (tACS) is a safe and patient-friendly non-invasive brain stimulation technique that serves as a potential candidate for reducing and/or slowing cognitive impairment. Application of tACS in the gamma frequency range, specifically around 40 Hz, has been studied in patients with AD and MCI due to AD. In these patients, a single session of 40 Hz tACS at the precuneus showed to improve episodic memory and to increase gamma power, as measured with electroencephalography. These findings will be replicated in the current study in patients with MCI due to AD, using magnetoencephalography (MEG) recorded before, during and after tACS. In this way, brain activity and network changes that underlie this improvement in episodic memory can be studied with greater temporal and spatial detail.

Enrollment

30 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Recent (not more than 6 months ago) amnestic MCI diagnosis, which consensus is obtained in a multidisciplinary meeting after an extended multidisciplinary test battery at the memory clinic, including confirmation of AD pathology with cerebrospinal fluid biomarkers: abnormal p-tau/Aβ42 ratio of > 0.023

Exclusion criteria

  • Suffering from serious neurological, psychiatric or somatic comorbidity
  • Suffering from epileptic seizures or severe claustrophobia
  • Intensive use of psychoactive medication
  • Having a cardiac pacemaker, internal cardiac defibrillator or other intracorporeal device that interferes with MEG recordings

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Quadruple Blind

30 participants in 2 patient groups

Active tACS
Experimental group
Description:
Gamma (40 Hz) tACS at the precuneus region
Treatment:
Device: Gamma (40 Hz) tACS at the precuneus region
Sham tACS
Sham Comparator group
Description:
Sham tACS at the precuneus region
Treatment:
Device: Sham tACS at the precuneus region

Trial contacts and locations

1

Loading...

Central trial contact

Willem de Haan, dr.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems